PDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization of royalty streams to companies and academic institutions.? Their market capitalization is $365 million and the stock is trading at $2.20 per share. ? Basically, what the company does is it finds patents that an institution or company has filed and then PDLI monetizes that patent.? Then, the company licenses the patent out taking in a spread between what the company pays to the patent holder and the fees collected by companies using the patent.? They are a middleman for the pharma patent industry. ? ? [more
PDL BioPharma Inc (PDLI) is traded on NASDAQ in USA. It is located in NEVADA, U.S.A and employs 10 people. PDL BioPharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 438.32 M. PDL BioPharma Inc has 154.34 M outstanding shares of which 19.07 M shares are at this time shorted by private and institutional investors with about 9.16 trading days to cover.
PDL BIOPHARMA INC currently holds about 516.49 M in cash with 73.72 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.35 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PDL BioPharma Probability Of Bankruptcy